FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/07/2026
Voltar para busca
Dado oficial do USPTO
HEALOME THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
23/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
27/02/2023
Data de registro
30/12/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/12/2025
Última transação
23/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
GB
Examinador
LINDEMYER, ANKHI MUKHERJEA
Unidade examinadora
N50
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of two intersecting ovals made up of small aqua, black, and navy circles with the wording "HEALOME THERAPEUTICS" located below in black. White in the mark is background and not a feature of the mark.
Titulares e representantes
Titulares
Healome Therapeutics Ltd
Representantes
Nicole M. Meyer Dickinson Wright PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substances and therapeutic pharmaceuticals for diseasestraumatic injuryperioperative careinflammation related to the eye; pharmaceutical preparationssubstances and treatments in the nature of eye dropssolutionsgelsfilms impregnated with preparations for the treatment of ocular and dermal conditionssterilized dressingssprayslubricantsointments used for treatment for ocular diseases and conditions; pharmaceutical preparationssubstances and treatments in the nature of eye dropssolutionsgelslubricantsointments used for treatment for ocular diseasesocular surface diseases and dry eye disease; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparationssubstances and treatments in the nature of solutionsgelsfilms impregnated with preparations for the treatment of ocular and dermal conditionssterilized dressingsspraysointments used for treatment for dermal diseases and conditions; pharmaceutical preparationssubstances and treatments in the nature of solutionsgelsfilms impregnated with preparations for the treatment of scarswounds and orthopaedic conditionsfor use in medical aesthetics treatmentssterilized dressingsspraysointments used for treatment for scar preventionwound healingmedical aesthetics and orthopaedic conditions; therapeutic preparations and substanceseye dropsocular lubricantssolutionsgelsfilms impregnated with preparations for the treatment of ocular diseasesocular conditionsocular surface diseases and dry eye diseasesterilized dressingssprayslubricantsointments for the treatment of ocular diseasesocular conditionsocular surface diseases and dry eye disease; gels for medical eye care; therapeutic gels for medical eye care; gel and liquid dropsspraysfilms for use as a delivery agent for drugs and for therapeutic pharmaceuticalssuspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditionssubstances in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gelssuspensionsliquids in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gelssuspensionsliquidslubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions and diseases; tear film substitutes to provide lubricationprovide protectionsupport homeostasisfor use as a delivery agent for drugs and supplements in the treatment of ocular conditions; tear film substitutes to provide lubricationprovide protectionsupport homeostasisfor use as a delivery agent for drugs and supplements for the treatment of eye conditions and diseases; gelssuspensionsliquidslubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditionsglaucomacataractsamblyopiaage-related macular degeneration and diabetes-related retinopathy; gelssuspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticalsliquids for medical and therapeutic usefor treating eye diseasestreating traumatic eye injuryused in perioperative eye care; eye drops; eye ointment for medical use; medicated eye-washes; eye lotions for medical use; lubricating eye drops; medicated liquids for the treatment of ocular diseases and conditions; medicated ocular lubricants; tear film substitutes being pharmaceutical preparations for the treatment of ocular diseasesinjuries and conditions; tear substitutesartificial tears for ocular diseases and conditions; tear film substitutesbeing pharmaceutical preparations in the form of eye dropssolutionsgelssprayslubricantsointments and artificial tears for treatment of ocular diseases and conditions;
Classe 42
Scientific and technological services and research and design relating theretoscientific research in the field of treatment of eye diseasesinjuries and conditionstreatment of dermal diseasesinjuries and conditionsin the field of biomaterials science; industrial scientific analysis and research services in the fields of eye care products and wound care products; product research and development services; scientific and technological services and research services relating theretoscientific research in the field of treatment of eye diseaseseye injuries and eye conditionstreatment of dermal diseasesinjuries and conditionsin the field of biomaterials science; scientific research services for medicalbiomedical and therapeutic purposes in the fields of ocular surface diseasesdry eye diseasesocular surface injurycorneal woundsglaucoma; medical and bioscience research services in the fields of ocular surface diseasesdry eye diseasesocular surface injurycorneal woundsglaucoma; biomedical research services; scientific research and development services relating to ocular diseasestreatment and conditions; research and development services relating to orthopaedics; scientific research and development services relating to dermatology; scientific research and development services relating to dermal applicationssuch as scar preventionwound healingmedical aesthetics; scientific research and development services relating to the treatment of diseases and conditions; scientific research services relating to the treatment of eye diseases and conditions; therapeutic research servicesscientific research in the field of eye diseases and eye injury; advisoryconsultancy and information services relating to all the aforesaid.
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/07/2026
FIMP
FINAL DISPOSITION PROCESSED
06/07/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/05/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/03/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/12/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
30/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/11/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/11/2025
PUBO
PUBLISHED FOR OPPOSITION
11/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/11/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/10/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
10/10/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/10/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
10/10/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/09/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/09/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/09/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/04/2025
GNRT
NON-FINAL ACTION E-MAILED
02/04/2025
CNRT
NON-FINAL ACTION WRITTEN
02/04/2025
DOCK
ASSIGNED TO EXAMINER
26/02/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
15/02/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/01/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
26/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/01/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/01/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
09/07/2024
GNFR
FINAL REFUSAL E-MAILED
09/07/2024
CNFR
FINAL REFUSAL WRITTEN
09/07/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/06/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/06/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/06/2024
RFNT
REFUSAL PROCESSED BY IB
03/01/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
13/12/2023
RFRR
REFUSAL PROCESSED BY MPU
13/12/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/12/2023
CNRT
NON-FINAL ACTION WRITTEN
04/12/2023
DOCK
ASSIGNED TO EXAMINER
28/11/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/10/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
25/10/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/10/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/10/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
25/10/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
25/10/2023
MAFR
APPLICATION FILING RECEIPT MAILED
05/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/09/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
31/08/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HEALOME THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.